Furthermore, Habibi et al. showed that the treatment with the SGLT2 inhibitors (empagliflozin) improved LV diastolic function in obese female mice with diabetes, even in the absence of a reduction in blood pressure and HbA1c [32]. Here, SLC5A2 is linked to diabetes mellitus.